Veriphi

Laser drug analyser that minimises the risk of intravenous drug error.

Background: Medical error is the third most common cause of death in the United States and medication error is one of the most common forms of patient harm in hospitals globally. Intravenous errors are twice as likely to harm patients, than from drugs given via other routes. Veriphi automatically verifies drug doses as they are compounded or administered and is paid every time that happens, providing greater safety by being seamless within existing clinical practise.

Update: Veriphi raised capital on Snowball Effect in 2016. Since then, the company has commenced trials with Auckland City Hospital Pharmacy and is completing assembly of five new redesigned commercial devices for compliance testing. Capital from the current offer will be used to complete hospital trials and compliance testing, before rolling out the product to commercial customers in the new year.

Sign up for early access.

You’ll receive an email notification and early access to the offer before it’s released to the wider public.



Note: This offer is not yet live. You should only make your investment decision once you have had a chance to review the final information memorandum and offer materials.